Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03048448 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03048448 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 42 participants.
The verdict
NCT03048448, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study will characterize the pharmacokinetics (PK) of QAW039 after a single oral dose of QAW039 in patients with hepatic impairment compared to healthy matched control subjects.
Interventions
- DRUG Fevipiprant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-05-31 |
| Est. Completion | 2019-04-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03048448
The ClinicalTrials.gov registry entry for NCT03048448 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fevipiprant is the first listed.
NCT03048448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03048448 about?
NCT03048448 is a clinical study titled "Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects". This study will characterize the pharmacokinetics (PK) of QAW039 after a single oral dose of QAW039 in patients with hepatic impairment compared to healthy matched control subjects.
What is the current status of trial NCT03048448?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2017-05-31. Estimated completion is 2019-04-22.
What interventions are being tested in trial NCT03048448?
The interventions under investigation include: Fevipiprant (DRUG).
Who is sponsoring clinical trial NCT03048448?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.